Indications：
ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult and adolescent over 12 years old patients who are anti-aquaporin-4 (AQP4) antibody positive.
This link will lead you to leave the website of Chugai Pharma Taiwan; the content of the linked website you choose (links, changes, or updates in this website) is no longer the responsibility of Chugai Pharma Taiwan. Chugai Pharma Taiwan does not take any legal responsibility for the information transmitted by this linked website.
This link is for your convenience only, and any link does not mean that Chugai Pharma Taiwan endorses or approves its website content.